 |
|
|
  |
|
|
|
|
| |
|
| Photomicrograph of a thrombus showing fibrin (yellow), red blood cells (red) and platelets (blue). |
|
| |
 |
|
Platelet GP IIb/IIIa Receptor Antagonists
Platelet GP IIb/IIIa Receptor Antagonists are used to prevent platelet aggregation. Platelet GP IIb/IIIa Receptors are plentiful on platelet surfaces and when platelets are activated, the configuration of this receptor changes to increase its affinity for binding to fibrinogen and other ligands. The Platelet GP IIb/IIIa Receptor Antagonists act by occupying the receptors and prevent fibrinogen binding, thus preventing platelet aggregation.1
|
Studies have shown that patients who have received GP IIb/IIIa Receptor Antagonists have a definite reduction in the composite end point of death, MI and the need for revascularization procedures.1
Three GP IIb/IIIa Receptor Antagonist agents are available and have been studied and found to be effective in numerous clinical trials— abciximab, eptifibatide and tirofiban.1
References |
|
|
 |
 |
 |
|
|
